Literature DB >> 34984595

Microrheological disorders in patients with polycythemia vera suffered acute ischemic stroke.

Marine Tanashyan1, Alla Shabalina2, Eugene Roitman3.   

Abstract

The relevance of the study is determined by the fact that the combination of cerebrovascular disorders and myeloproliferative diseases requires the search for a predictive biomarker to improve outcomes. The aim of this article was to explore the meanings of microrheological disorders in patients with polycythemia vera (PV) who suffered an acute ischemic stroke (AIS). The study was carried out at the Research center of Neurology. We studied microrheological properties in 181 patients (aged 42-75 years). From the AIS developed in 68 (38%) patients with PV; 59 (32%) patients with AIS were without PV; 54 (30%) patients with PV did not suffer AIS. Microrheological disorders, first of all, the red blood cells (RBC) deformability correlated to AIS severity and its features in comorbid patients. The RBC deformability was dependent on the allelic load of the V617F mutation in the JAK2 gene. Additionally, it was found that RBC deformability perform diagnostic value in the acute phase of ischemic stroke as well as get predictive value for thrombotic complications development within 2 years after AIS in such patients. We suppose that in patients with PV an ischemic stroke and thrombosis would directly depend on the success of PV treatment. In turn, RBC deformability is applicable for some predictive models to late thrombosis development.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Erythrocyte deformability; Myeloproliferative diseases; Stroke; Thrombotic complications; Vascular disease

Mesh:

Year:  2022        PMID: 34984595     DOI: 10.1007/s11010-021-04352-6

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  9 in total

1.  Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.

Authors:  Alessandra Carobbio; Guido Finazzi; Vittoria Guerini; Orietta Spinelli; Federica Delaini; Roberto Marchioli; Giovanna Borrelli; Alessandro Rambaldi; Tiziano Barbui
Journal:  Blood       Date:  2006-11-16       Impact factor: 22.113

2.  Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis.

Authors:  C James; F Delhommeau; C Marzac; I Teyssandier; J-P Le Couédic; S Giraudier; L Roy; P Saulnier; L Lacroix; S Maury; M Tulliez; W Vainchenker; V Ugo; N Casadevall
Journal:  Leukemia       Date:  2006-02       Impact factor: 11.528

3.  Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.

Authors:  Alessandra Carobbio; Juergen Thiele; Francesco Passamonti; Elisa Rumi; Marco Ruggeri; Francesco Rodeghiero; Maria Luigia Randi; Irene Bertozzi; Alessandro M Vannucchi; Elisabetta Antonioli; Heinz Gisslinger; Veronika Buxhofer-Ausch; Guido Finazzi; Naseema Gangat; Ayalew Tefferi; Tiziano Barbui
Journal:  Blood       Date:  2011-04-13       Impact factor: 22.113

4.  Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms.

Authors:  Giuseppe Cella; Marina Marchetti; Fabrizio Vianello; Marina Panova-Noeva; Alfonso Vignoli; Laura Russo; Tiziano Barbui; Anna Falanga
Journal:  Thromb Haemost       Date:  2010-04-29       Impact factor: 5.249

5.  The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK.

Authors:  B K MacDonald; O C Cockerell; J W Sander; S D Shorvon
Journal:  Brain       Date:  2000-04       Impact factor: 13.501

6.  From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.

Authors:  Mario Cazzola; Robert Kralovics
Journal:  Blood       Date:  2014-04-30       Impact factor: 22.113

7.  Cocaine Use and Risk of Ischemic Stroke in Young Adults.

Authors:  Yu-Ching Cheng; Kathleen A Ryan; Saad A Qadwai; Jay Shah; Mary J Sparks; Marcella A Wozniak; Barney J Stern; Michael S Phipps; Carolyn A Cronin; Laurence S Magder; John W Cole; Steven J Kittner
Journal:  Stroke       Date:  2016-03-10       Impact factor: 7.914

Review 8.  Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.

Authors:  Elisa Rumi; Mario Cazzola
Journal:  Blood       Date:  2016-12-27       Impact factor: 22.113

Review 9.  Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis.

Authors:  Victor R Gordeuk; Nigel S Key; Josef T Prchal
Journal:  Haematologica       Date:  2019-03-14       Impact factor: 9.941

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.